Ten stocks boasted strong double- to triple-digit gains last week, outperforming a mostly optimistic US market amid US and Iran’s efforts for a peace deal.
Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, while some favored pharmaceutical players thanks to progress on their pipeline drugs.
In this article, we name the 10 best performers last week and detail the reasons behind their gains.
To come up with the list, we only considered the stocks with a $2 billion market capitalization and based their rankings on the percentage growth in their share prices on April 10 and 17, 2026.
The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
10. Travere Therapeutics Inc. (NASDAQ:TVTX)
Travere Therapeutics grew its share prices by 40.78 percent week-on-week, as investors increased their positions after securing the approval of the Food and Drug Administration (FDA) for its kidney disease treatment, Filspari.
In a statement earlier in the week, Travere Therapeutics Inc. (NASDAQ:TVTX) said that the FDA has given the green light for Filspari to treat patients aged 8 and above who are suffering from focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. It is the only medicine approved by the FDA to treat FSGS.
The approval followed the successful phase 3 study of the drug, which saw a 46 percent reduction in proteinuria at week 108, as compared with the 30 percent for those treated with the maximum labeled dose of irbesartan.
Travere Therapeutics Inc. noted that Filspari demonstrated even greater improvements in patients without nephrotic syndrome, versus the maximum labeled dose of irbesartan across proteinuria and eGFR.
“This approval reflects years of perseverance and our belief that those living with FSGS deserve better. It also builds on our leadership and progress in rare kidney diseases, expanding Filspari’s potential reach to more than 100,000 people in the US with FSGS and IgAN (IgA nephropathy) who need better treatment options,” said Travere Therapeutics Inc. President and CEO Eric Dube.
“Filspari will be available for nephrologists to immediately prescribe to individuals with FSGS. We are profoundly grateful to the patients, caregivers, investigators, healthcare providers, regulators and advocates who made this moment possible,” he noted.
9. Spyre Therapeutics Inc. (NASDAQ:SYRE)
Spyre Therapeutics grew its share prices by 42.3 percent week-on-week, as investors took heart from the “best-in-class” potential of its therapy candidate for ulcerative colitis (UC).
In an updated report earlier in the week, Spyre Therapeutics Inc. (NASDAQ:SYRE) said that its treatment candidate, SPY001, saw a clinical remission rate of 40 percent at 12 weeks versus Entyvio’s 27 percent at 14 weeks.
The drug also achieved a 51 percent improvement in endoscopic versus its competitor’s 41 percent at six weeks.
Following the news, investment firm BTIG upgraded its price target for Spyre Therapeutics Inc. to $98 from $70 previously, while maintaining a “buy” recommendation.
BTIG also raised to 80 percent its expectations for SPY001 combinations to succeed, as well as penetration rates for UC and Crohn’s disease to 30 and 20 percent, respectively.
In other news, Spyre Therapeutics Inc. kicked off a $300 million share sale in line with plans to raise funds to support its pipeline programs.
It also granted its underwriters a $45 million overallotment option at the same price for 30 days from the public offering date.
8. Hims & Hers Health Inc. (NYSE:HIMS)
Hims & Hers saw its share prices jump by 48.3 percent week-on-week as investors positioned portfolios ahead of the results of its earnings performance for the first quarter of the year, supported by optimism over its rekindled partnership with Novo Nordisk.
In an updated report, Hims & Hers Health Inc. said that it is scheduled to release the results of its earnings performance after market close on May 11, 2026. A conference call will be held to elaborate on the results.
For the period, the company expects to grow its year-on-year revenues by 2.4 percent to 6.7 percent to a range of $600 million to $625 million, versus $586 million in the same period a year earlier.
Adjusted EBITDA is projected at a range of $35 million to $55 million, or a decline of 40 percent to 61.6 percent from the $91.1 million in the same comparable period.
Investors are also expected to watch for Hims & Hers Health Inc.’s outlook for the second quarter of the year after it renewed its partnership with Novo Nordisk for the sale of the latter’s Wegovy and Ozempic on the HIMS platform. The partnership initially began last year but was terminated a month later after Novo accused Hims of “failing to adhere to the law” by continuing to sell its compounded GLP-1 drugs.
In the newly inked contract, Hims & Hers Health Inc. committed to sell only the FDA-approved weight loss drugs, while the compounded GLP-1 versions will be offered only in cases where the needs of the customers cannot be met using the FDA-approved version, and if a provider determines that a compounded product is clinically necessary.
7. NextNav Inc. (NASDAQ:NN)
NextNav rallied by 49.4 percent week-on-week, as investors took heart from a flurry of developments, including analyst expectations that it could become an acquisition target.
In a market note earlier in the week, Oppenheimer said that NextNav Inc. (NASDAQ:NN) could be an acquisition target on expectations that it would secure the approval of the Federal Communications Commission (FCC) for its spectrum rebranding plans.
If approved, the listed firm is expected to receive an additional 1MHz of spectrum, giving it continuous 15MHz in the lower 900MHz band for a total of 5.1 billion MHz-POPs.
The additional spectrum means that NextNav Inc. would be able to serve a larger number of people more effectively.
In line with the projections, Oppenheimer upgraded NextNav Inc. to “outperform” from “perform” previously, while assigning a $25 price target, or a 9.5 percent upside potential from its latest closing price. Friday also marked its seventh straight day of gains.
In other developments, NextNav Inc. last Thursday secured the FCC approval to conduct a field test to validate the coexistence between its proposed 5G operations and the licensed operations of railroad automatic equipment identification systems in Pueblo, Colorado.
6. D-Wave Quantum Inc. (NYSE:QBTS)
D-Wave Quantum soared by 52.2 percent week-on-week amid a combination of broader market optimism and Nvidia Corp.’s launch of two new products aimed at solving the challenges in the quantum computing industry.
Earlier in the week, D-Wave Quantum Computing Inc. (NYSE:QBTS) climbed alongside its counterparts Rigetti, IonQ, and Infleqtion, among others, following Nvidia’s launch of a new AI-powered workflow designed to correct quantum systems’ biggest problems.
Called the Ising Calibration and Ising Decoding, Nvidia said that the two model domains can both target the fundamental challenges in quantum computing.
Ising Calibration is a vision-language model for automating QPU calibration tasks capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.
Investors took the development positively, sparking appetite for key players, including D-Wave Quantum Computing Inc., as it validated the increasing importance of the quantum sector after tech executives last year said that they deem the industry useful only decades away.
5. Revolution Medicines Inc. (NASDAQ:RVMD)
Revolution Medicines soared by 54.13 percent week-on-week, with sentiment primarily bolstered by the stellar results of its clinical trial for its pancreatic cancer treatment, while taking heart from bullish recommendations from analysts.
In an updated report, Revolution Medicines Inc. (NASDAQ:RVMD) said that its therapy candidate, Daraxonrasib, recorded a median overall survival of 13.2 months during its late-stage clinical study, as compared with 6.7 months for chemotherapy alone.
“Daraxonrasib, as a targeted medicine, delivered a dramatic improvement in overall survival in patients with previously treated metastatic pancreatic cancer compared to standard of care chemotherapy, consistent with earlier findings. These results represent a potentially transformative advance for patients and underscore daraxonrasib’s potential to redefine the treatment landscape,” Revolution Medicines Inc. Chairman and CEO Mark Goldsmith said.
Following the results, the company said that it is now “moving with urgency” toward global regulatory submissions, including the filing of a new drug application with the Food and Drug Administration (FDA).
Revolution Medicines Inc. earned a “strong buy” recommendation from investment firm Raymond James, alongside a 30-percent price target hike of $175, versus $135 previously.
Meanwhile, Bank of America gave a $170 price target, or a 48 percent upgrade from $115, while maintaining a “buy” recommendation.
Jim Cramer, former hedge fund manager and host of the Mad Money show on CNBC, underscored the company’s slashing of death risk by 60 percent.
“That’s rather extraordinary. And … they’re gonna seek FDA approval, Commissioner’s national priority voucher. But what matters here is that Merck, just reportedly, was trying to buy it for $28 to $32 billion, well in excess of what they wanted to buy it, so, you could argue, why did they buy it?”
4. IonQ Inc. (NYSE:IONQ)
IonQ saw its share prices jump by 60 percent week-on-week, thanks to Nvidia Corp.’s launch of two new products, which solidified the importance of the quantum computing industry.
IonQ Inc. (NYSE:IONQ) grew alongside its counterparts earlier in the week after Nvidia unveiled a new AI-powered workflow designed to correct quantum systems’ biggest problems.
Called the Ising Calibration and Ising Decoding, Nvidia said that the two model domains can both target the fundamental challenges in quantum computing.
Ising Calibration is a vision-language model for automating QPU calibration tasks capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.
Investors took the development positively, sparking appetite for key players as it validated the increasing importance of the quantum sector after executives from technology giants earlier said that they deem the industry useful only decades away.
In other news, IonQ Inc. said that it would release the results of its earnings performance in the first quarter of the year after market close on May 6, 2026. A conference call will be held to elaborate on the results.
Earlier this week, IonQ Inc. announced a new milestone in photonically interconnecting two independent trapped-ion quantum systems, bolstering its targets of moving to distributed, networked architectures from individual quantum processors at present.
“Scaling quantum computation beyond the limits of a single chip is essential for realizing a future quantum internet. This demonstration proves that our trapped-ion platform is uniquely suited for the high-fidelity networking required to solve the world’s most complex problems,” CEO Niccolo de Masi said.
3. Avis Budget Inc. (NASDAQ:CAR)
Avis Budget zoomed by 64.6 percent week-on-week, primarily driven by last week’s developments in the Middle East.
The rally can also be attributed to the stock’s short interest, which forced bearish investors to rapidly cover positions as prices climbed.
It is also worth noting that Avis Budget Group Inc. (NASDAQ:CAR) is a highly shorted company, with at least 20 percent of its float sold short, giving room for potential breakout rallies.
Short-selling aside, Avis Budget Inc. is benefitting from the uncertainties in the ongoing peace talks between the US and Iran, whose war over the past few weeks has sent global crude oil prices spiking.
This, on the other hand, sparked good news for used car and car rental stocks like Avis Budget Group Inc. and Hertz Global Holdings, as travelers look for alternative modes of transportation to mitigate risks from the oil spikes.
Last year, the company narrowed its net loss by 51 percent to $889 million from $1.82 billion in 2024. Revenues decreased by 1.6 percent to $11.6 billion from $11.79 billion year-on-year.
In the fourth quarter alone, Avis Budget Group Inc. incurred an attributable net loss of $747 million, or 61.8 percent lower than the $1.958 billion year-on-year. Revenues dipped 1.7 percent to $2.66 billion from $2.7 billion year-on-year.
2. Maase Inc. (NASDAQ:MAAS)
Maase surged by 83.9 percent week-on-week, as investors loaded portfolios in companies riding the AI boom, supported by the broader market optimism during the week.
Further buoying sentiment was news earlier that it successfully established its position as a full-stack AI company following the acquisition of an entire stake in Times Good Ltd., which owns the core assets and operations of Huazhi Future (Chongqing) Technology Co., Ltd. and its subsidiaries.
“This acquisition marks a pivotal milestone in MAAS’s strategic evolution. Huazhi Group’s underlying technology stack is highly synergistic and complementary to our existing business landscape,” Maase Inc. (NASDAQ:MAAS) CEO Min Zhou said.
“Going forward, we will accelerate the deep integration of our technical architectures and core talent pools, focusing on mission-critical benchmark scenarios including energy dispatch optimization, intelligent commercial networks, and urban comprehensive governance. We remain committed to pushing the boundaries of AI applications and continuously enhancing our industry-leading AI ecosystem matrix,” she added.
Huazhi Group specializes in high-performance computing and artificial intelligence algorithm research and development, spanning computing power resource integration and cutting-edge algorithm development. It has accumulated extensive domain expertise in smart governance, encompassing public security, emergency management, agriculture, forestry, and water resources, and enterprise digital transformation.
Post-acquisition, Maase Inc. said that it will vertically integrate underlying computing infrastructure, proprietary algorithms, intelligent hardware, and full-spectrum operational services, creating a closed-loop, full-stack AI technology and operational ecosystem spanning the entire industry value chain.
1. Xanadu Quantum Technologies Ltd. (NASDAQ:XNDU)
Xanadu Quantum soared by 237 percent week-on-week, as investors loaded positions in quantum stocks after Nvidia Corp.’s unveiling of two new models aimed at solving the challenges of the quantum computing industry.
Nearly a month after it debuted on the stock market, Xanadu Quantum Technologies Ltd. (NASDAQ:XNDU) has already seen its stock price surge by as much as 430 percent, having hit its highest price of $42.44 at intra-day trading on Thursday.
Earlier in the week, Xanadu Quantum Technologies Ltd. climbed alongside its counterparts Rigetti, IonQ, and Infleqtion, among others, following Nvidia’s launch of a new AI-powered workflow designed to correct quantum systems’ biggest problems.
Called the Ising Calibration and Ising Decoding, Nvidia said that the two model domains can both target the fundamental challenges in quantum computing.
Ising Calibration is a vision-language model for automating QPU calibration tasks capable of understanding quantum computing scientific experiment output and how it compares to expected trends, while Ising Decoding consists of two 3D CNN models for demanding decoding needed during quantum error correction.
Investors took the development positively, sparking appetite for key players, including Xanadu Quantum Technologies Ltd., as it validated the increasing importance of the quantum sector after executives from technology giants earlier said that they deem the industry useful only decades away.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
